<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489097</url>
  </required_header>
  <id_info>
    <org_study_id>NAC 08-021</org_study_id>
    <secondary_id>Enigma II nested NCT00430989</secondary_id>
    <nct_id>NCT02489097</nct_id>
  </id_info>
  <brief_title>International Substudy Enigma2 on Postoperative Cognitive Disorders</brief_title>
  <acronym>ISEP</acronym>
  <official_title>Evaluating the Incidence and Association Between Nitrous Oxide and Postoperative Cognitive Disorders in Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prince of Wales Hospital, Shatin, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a substudy of the Enigma2 trial (NCT00430989) which aims at investigating the&#xD;
      effectiveness and safety of nitrous oxide (N2O) in anaesthesia.The substudy focus is on&#xD;
      postoperative cognitive disorders.&#xD;
&#xD;
      Substudy Hypothesis: In patients undergoing anaesthesia for major surgery, administration of&#xD;
      N2O will reduce postoperative cognitive disorders when compared with otherwise identically&#xD;
      managed surgical patients not receiving N2O as a component of their anaesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous studies questioned the routine use of nitrous oxide (N2O), the oldest anaesthetic&#xD;
      agent used since the development of anaesthesia care. Despite its wide use, there is&#xD;
      sufficient doubt as to the risk-benefit profile.&#xD;
&#xD;
      There is strong evidence that N2O is a major risk factor for postoperative nausea and&#xD;
      vomiting. It is clear that (even) brief exposure to N2O impairs methionine synthetase, an&#xD;
      enzyme required for DNA production, red and white blood cell formation. Tissue hypoxia may be&#xD;
      more common. These adverse effects are enhanced in &quot;sick&quot; patients (ie. those at highest&#xD;
      risk, with increased hospital length of stay and healthcare expenditure), and will be more&#xD;
      likely in longer surgery. At the same time, observational studies and subgroup analysis of&#xD;
      published trials suggest that N2O may have beneficial effects in preventing pain and&#xD;
      postoperative cognitive disorders&#xD;
&#xD;
      Outcome trial data on postoperative cognitive disorders are lacking in this area for an&#xD;
      anaesthetic gas used in more than 90% of all surgery around the world. The enigma2 substudy&#xD;
      as a nested study of the large Enigma2 randomised controlled trial aims at answering this&#xD;
      question.&#xD;
&#xD;
      The investigators aim at recruiting 420 patients in 2 of the 25 centres participating to the&#xD;
      Enigma 2 trials, who are undergoing major surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis results showed futility&#xD;
  </why_stopped>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Memory, Executive function, Attention and psychomotor speed testing battery</measure>
    <time_frame>Baseline before surgery</time_frame>
    <description>Validated Computerized testing battery developed by the University of Cambridge for cognitive testing (CANTAB). Patients are tested for baseline cognitive function before surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Memory, Executive function, Attention and psychomotor speed using CANTAB Cognitive testing battery at 7days following surgery</measure>
    <time_frame>First assessment (7 days)</time_frame>
    <description>Validated Computerized testing battery developed by the University of Cambridge for cognitive testing (CANTAB). Patients are tested for changes from the baseline cognitive function (before surgery) at 7 days after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Memory, Executive function, Attention and psychomotor speed using CANTAB Cognitive testing battery at 3 months following surgery</measure>
    <time_frame>Second assessment (3 months)</time_frame>
    <description>Validated Computerized testing battery developed by the University of Cambridge for cognitive testing (CANTAB). Patients are tested for changes from the baseline cognitive function (before surgery) at 3 months after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>up to a maximum of 3 months</time_frame>
    <description>Planned and unplanned admission to the ICU and ICU duration of stay; Follow up to be performed for the whole duration of hospital stay and up to a maximum of 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>up to a maximum of 3 months</time_frame>
    <description>Duration of stay in Hospital; Follow up to be performed for the whole duration of hospital stay and up to a maximum of 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Use of the validated EuroQol test (EQ-5D questionnaire http://www.euroqol.org/)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Anesthesia</condition>
  <condition>Delirium, Dementia, Amnestic, Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives a mixture of 70% Nitrous Oxide in 30% Oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Air/Oxygen (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receives a mixture of 70% Air in 30% Oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide</intervention_name>
    <description>Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture</description>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <other_name>N2O</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture</description>
    <arm_group_label>Air/Oxygen (placebo)</arm_group_label>
    <other_name>Air/Oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult males and females aged ≥ 45 years, undergoing noncardiac surgery and general&#xD;
        anaesthesia that exceeds two hours.&#xD;
&#xD;
        At increased risk of cardiac events, defined as any of:&#xD;
&#xD;
          -  history of coronary artery disease (angina, MI, Coronary revascularisation-Coronary&#xD;
             Artery Bypass Graft (CABG) and Percutaneous Transluminal Coronary Angiography (&#xD;
             PTCA)-, positive stress testing, angiography/other imaging, Q waves on ECG)&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  cerebrovascular disease due to atherothrombotic disease&#xD;
&#xD;
          -  aortic or peripheral vascular disease&#xD;
&#xD;
        OR&#xD;
&#xD;
        three or more of the following risk factors: age ≥70 years, history of heart failure,&#xD;
        diabetes (medicated), hypertension (medicated), preoperative serum creatinine &gt;175 mmol/L,&#xD;
        cholesterol ≥6.2 mmol/L, history of a transient ischemic attack (TIA),&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dementia (MMS test≤24)&#xD;
&#xD;
          2. Parkinson Disease&#xD;
&#xD;
          3. Patients taking regularly (&gt;2 weeks) tricyclic antidepressants or neuroleptics&#xD;
&#xD;
          4. Patients suffering from Alcohol Dependency (WHO CRITERIA )&#xD;
&#xD;
          5. Patients suffering from severe hypoacusis or visual loss or any other reason hindering&#xD;
             the CANTAB battery testing process&#xD;
&#xD;
          6. Patients with untreated deficit in Vitamin B6, B12 and folic acid&#xD;
&#xD;
          7. Patients with marked impairment of gas-exchange requiring Fi02&gt; 0.5 intraoperatively&#xD;
&#xD;
          8. Patients with specific circumstances where N2O is contraindicated (eg. volvulus,&#xD;
             pulmonary hypertension, raised intracranial pressure) or the use of supplemental&#xD;
             oxygen is planned (eg. colorectal surgery)&#xD;
&#xD;
          9. N2O unavailable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myles Paul, MD, FANZCA</last_name>
    <role>Study Chair</role>
    <affiliation>Bayside Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1203</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Chan MTV, Wan ACM, Gin T, Leslie K, Myles PS. Chronic postsurgical pain after nitrous oxide anesthesia. Pain. 2011 Nov;152(11):2514-2520. doi: 10.1016/j.pain.2011.07.015. Epub 2011 Sep 1.</citation>
    <PMID>21889262</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008 Oct;109(4):707-22. doi: 10.1097/ALN.0b013e3181870a17. Review.</citation>
    <PMID>18813051</PMID>
  </results_reference>
  <results_reference>
    <citation>Myles PS, Leslie K, Chan MT, Forbes A, Paech MJ, Peyton P, Silbert BS, Pascoe E; ENIGMA Trial Group. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology. 2007 Aug;107(2):221-31.</citation>
    <PMID>17667565</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>December 12, 2020</last_update_submitted>
  <last_update_submitted_qc>December 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Dr Guy Haller</investigator_full_name>
    <investigator_title>Staff Anaesthetist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

